InGel Tx is a Harvard cell-based therapy biotech focusing on novel neuroprotective mechanism in the eye to stop and repair retinal degeneration. Our core technology combines expertise across stem cell biology, genetics and biomaterials, with some of the best scientific founders and advisors such as Professor Michael Young and Professor Connie Cepko from Harvard Medical School.